Last $2.47 USD
Change Today +0.01 / 0.41%
Volume 19.7K
BOTA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

biota pharmaceuticals inc (BOTA) Snapshot

Open
$2.46
Previous Close
$2.46
Day High
$2.48
Day Low
$2.41
52 Week High
03/6/14 - $7.07
52 Week Low
09/17/14 - $2.10
Market Cap
86.7M
Average Volume 10 Days
26.9K
EPS TTM
$-0.31
Shares Outstanding
35.1M
EX-Date
11/9/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTA PHARMACEUTICALS INC (BOTA)

Related News

No related news articles were found.

biota pharmaceuticals inc (BOTA) Related Businessweek News

No Related Businessweek News Found

biota pharmaceuticals inc (BOTA) Details

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing oral, small molecule compounds to treat various respiratory-related viral infections. Its advanced clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor for the treatment of influenza A and B. The company also develops vapendavir, which completed Phase II trials for the treatment of human rhinovirus infections in patients with moderate to severe asthma, as well as completed additional Phase 1 bioavailability and drug-drug interaction studies. In addition, it develops orally bioavailable F and non-F protein compounds for the treatment of respiratory syncytial virus infections in children, the elderly, and immune-compromised patients. Biota Pharmaceuticals, Inc. is headquartered in Alpharetta, Georgia.

66 Employees
Last Reported Date: 09/30/14

biota pharmaceuticals inc (BOTA) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $408.0K
Executive Chairman
Total Annual Compensation: $525.0K
Vice President of Human Resources
Total Annual Compensation: A$237.9K
Vice President of Research
Total Annual Compensation: A$332.3K
Vice President of Product Development and Str...
Total Annual Compensation: A$312.4K
Compensation as of Fiscal Year 2014.

biota pharmaceuticals inc (BOTA) Key Developments

Biota Pharmaceuticals, Inc. Announces Management Changes, Effective October 1, 2014

Biota Pharmaceuticals, Inc. announced that executive vice president of corporate development and strategy, Joseph Patti, will assume the role of president and chief executive officer, replacing Russell H. Plumb, the company's current president and chief executive officer. Russel Plumb, the company's current president and chief executive officer will step down as president and chief executive officer and will assume the role of executive chairman of the board of directors and will continue to have certain other ongoing responsibilities with the company. Current chairman James Fox will step down as chairman of the board and will assume role of lead independent director. Dr. Patti joined the company on November 12, 2012 and has served as it’s executive vice president of corporate development and strategy since that time. Prior to joining the company, Dr. Patti was a co-founder of Inhibitex, Inc. and served as it’s chief scientific officer and senior vice president of research and development from 2007 until it was acquired by Bristol Myers Squibb in February 2012. Dr. Patti is currently a director of SciStem Therapeutics, Inc. The changes to management and its board of directors will become effective October 1, 2014.

Biota Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2014

Biota Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended June 30, 2014. For the quarter, the company reported total revenue of $8.5 million compared to $9.3 million a year ago. Loss from operations was $10.5 million compared to $6.4 million a year ago. Loss before tax was $10.4 million compared to $6.3 million a year ago. Net loss was $10.2 million compared to $6.5 million a year ago. Basic and diluted loss per share was $0.29 compared to $0.23 a year ago. For the year, the company reported total revenue of $68.7 million compared to $33.6 million a year ago. Loss from operations was $11.5 million compared to $22.1 million a year ago. Loss before tax was $11.3 million compared to $8.8 million a year ago. Net loss was $11.0 million compared to $8.9 million a year ago. Basic and diluted loss per share was $0.35 compared to $0.32 a year ago.

Biota Pharmaceuticals, Inc. to Report Q4, 2014 Results on Sep 26, 2014

Biota Pharmaceuticals, Inc. announced that they will report Q4, 2014 results on Sep 26, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOTA:US $2.47 USD +0.01

BOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Roche Holding AG SFr.274.70 CHF +6.10
View Industry Companies
 

Industry Analysis

BOTA

Industry Average

Valuation BOTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTA PHARMACEUTICALS INC, please visit www.biotapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.